Results from most studies have not been able to detect an increased teratogenic risk associated with the use of inhaled budesonide. The administration of budesonide during pregnancy requires that the benefits for the mother be weighed against the risk for the foetus. Inhaled glucocorticosteroids should be considered in preference to oral glucocorticosteroids because of the lower systemic effects at the doses required to achieve similar pulmonary responses. Budesonide is excreted in breast milk. However, at therapeutic doses of Talgan nebuliser suspension, no effects on the suckling child are anticipated. Talgan nebuliser suspension can be used during breastfeeding.